Abigail Brooks, MA

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

Findings highlight the prognostic value of metabolic syndrome components in predicting both renal and cardiovascular outcomes in patients with IgA nephropathy.

Shiffman reviews some of the key findings from AHFIRM, explaining important considerations for interpreting the results and potential reasons for regional differences in the data.

This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.

Shiffman describes the current treatment landscape for alcohol-associated hepatitis and what larsucosterol might offer for these patients.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

Study results highlight the impact of continuous glucose monitoring on glucose control and HbA1c improvements in patients with type 2 diabetes, regardless of treatment regimen.

Teva Pharmaceuticals’ launch of an authorized generic of liraglutide injection 1.8 mg (Victoza) for type 2 diabetes makes it the first-ever generic GLP-1.

Participants assigned to a 4-day energy balance diet plus oral bisphenol A administration at 50 μg/kg body weight experienced significant decreases in peripheral insulin sensitivity.

New phase 1/2 data suggest VX-880 islet cell therapy may restore physiological islet function and glycemic control in patients with T1D, potentially eliminating the need for insulin use.

Loftus explains the significance of IL-23 and Th17 in IBD and key trial data supporting the FDA approval of risankizumab in ulcerative colitis.

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

Ross-Driscoll explains how disparities in the liver transplant process begin prior to waitlisting and how findings from her research on referral and evaluation may inform interventions.

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Findings suggest machine learning models may have promising utility in IgAN, highlighting the superior diagnostic performance of certain models versus standard logistic regression.

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

Interim analyses of a pair of phase 2b studies highlight the IBAT inhibitor’s potential in adults with primary biliary cholangitis and primary sclerosing cholangitis.

The network meta-analysis found tenofovir disoproxil fumarate was more likely to achieve virologic response at week 48, while entecavir was superior for 48-week biochemical response.

Lower free thyroxine levels were linked to worse renal outcomes in patients with IgAN, and free thyroxine with tubular atrophy/interstitial fibrosis had high predictive value for IgAN prognosis.

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Survey results called attention to gaps in physicians’ clinical knowledge of IgAN, with incorrect responses prevalent among both specialists and generalists.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

Results showed eGFR was linked to having ≥ 20 adult teeth in postmenopausal women, highlighting increased tooth loss among participants with CKD versus those without.

Data collected from parallel online surveys revealed notable differences in IgA nephropathy treatment among patients and nephrologists from the US, EU5, Japan, and China.

A post-hoc analysis of the phase 2b ORIGIN study highlights atacicept’s impact on hematuria, with more patients achieving improvement and resolution at 36 weeks than those on placebo.